| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24004 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 02/02/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/02/2024 |
| Pre-submission consultation with Applicant | 09/04/2024 |
| Full submission received from Applicant | 22/08/2024 |
| Preliminary review sent to Applicant | 14/05/2025 |
| NCPE assessment re-commenced | 26/06/2025 |
| Factual accuracy sent to Applicant | 11/08/2025 |
| NCPE assessment re-commenced | 18/08/2025 |
| NCPE assessment completed | 11/09/2025 |
| NCPE assessment outcome | The NCPE recommends that dostarlimab, in combination with carboplatin plus paclitaxel, for the first-line treatment of adult patients with dMMR/MSI-H primary advanced or recurrent EC, and who are candidates for systemic therapy, be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.